LH vs OPK
LH: Labcorp is a leading global life sciences company providing essential clinical diagnostic testing and drug development services to the healthcare industry. OPK: OPKO Health is a multi-segment healthcare company balancing an R&D pharmaceutical pipeline with established clinical laboratory diagnostic services.
Side-by-side fundamentals
| Metric | LH | OPK | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $314.20 | $1.37 | |
| Market cap | $25.5B | $1.0B | |
| P/E as of 2026-10-08 | 25.98 | n/a | |
| Net margin FY2025, SEC XBRL | +6.3% | -37.2% | LH higher |
| Gross margin FY2025, SEC XBRL | +28.8% | +33.9% | OPK higher |
| Operating margin FY2025, SEC XBRL | +9.9% | -19.3% | LH higher |
| ROE FY2025, SEC XBRL | +10.2% | -17.8% | LH higher |
| ROA FY2025, SEC XBRL | +4.8% | -11.7% | LH higher |
| Debt / equity as of 2026-09-03 | 0.69 | 0.30 | OPK lower |
| Revenue growth (YoY) as of 2026-09-03 | +6.4% | -29.0% | LH higher |
| Revenue CAGR (3y) SEC XBRL | +5.6% | -15.5% | LH higher |
| Dividend yield as of 2026-09-03 | +0.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 4 | 0 | LH higher |
| Beta as of 2026-09-03 | 0.54 | 0.81 | |
| 1-year return as of 2026-10-08 close | +13.2% | -11.6% | LH higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.